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ABSTRACT 
Study Objectives: 
To estimate the economic cost (financial and non-financial) of inadequate sleep in 
Australia for the 2016-17 financial year and relate this to likely costs in similar 
economies. 
Methods: 
Analysis was undertaken using prevalence, financial and non-financial cost data 
derived from national surveys and databases. Costs considered included: (a) financial 
costs associated with health care, informal care provided outside healthcare sector, 
productivity losses, non-medical work and vehicle accident costs, deadweight loss 
through inefficiencies relating to lost taxation revenue and welfare payments; and (b) 
nonfinancial costs of loss of well-being. They were expressed in US dollars ($). 
Results: 
The estimated overall cost of inadequate sleep in Australia in 2016-17 (population: 
24.8 million) was $45.21 billion. The financial cost component was $17.88 billion, 
comprised of: direct health costs of $160 million for sleep disorders and $1.08 billion 
for associated conditions; productivity losses of $12.19 billion ($5.22 billion  reduced 
employment, $0.61 billion premature death, $1.73 billion absenteeism, $4.63 billion 
presenteeism); non-medical accident costs of $2.48 billion; informal care costs of 
$0.41 billion; and deadweight loss of $1.56 billion. The non-financial cost of reduced 
well-being was $27.33 billion.  
Conclusions: 
The financial and non-financial costs associated with inadequate sleep are substantial. 
The estimated total financial cost of $17.88 billion represents 1.55% of Australian 
gross domestic product. The estimated non-financial cost of $27.33 billion represents 
4.6% of the total Australian burden of disease for the year. These costs warrant 
substantial investment in preventive health measures to address the issue through 
education and regulation. 
 
 
KEY WORDS 
Inadequate sleep, sleep disorders, sleep deprivation, medical economics, public 
health 
 
3 
 
STATEMENT OF SIGNIFICANCE 
Inadequate sleep is a substantial public health problem regularly affecting more than 
one in three adults. While partly related to clinical sleep disorders and other health 
complaints, much appears to due to work or life-style related sleep restriction.  Health, 
well-being, productivity and safety suffer. Besides their human cost, these 
consequences have an economic cost which the present study demonstrates is very 
substantial.  The importance of such an analysis is that political and administrative 
decisions are largely based on economic data. As there is strong competition for health 
and preventive health funds, sleep health advocates must establish how inadequate 
sleep ranks alongside other health and social problems in terms of societal and 
financial cost and associated communal illness and injury burden. 
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INTRODUCTION 
 
Sleep is under unprecedented challenge as technological advances increase the 
pressures on it and the temptations to truncate it in an effort to create more time for 
wakeful work, social and family activities.1 Developments in communication 
technologies within and across time zones, web based information and entertainment 
platforms and social media have each played a role in this.  Furthermore, there is 
evidence of increasing prevalence of common sleep disorders such as insomnia and 
obstructive sleep apnea, in part due to the pressures, sedentariness and other lifestyle 
changes that accompany these modern pursuits.2,3 
 
Community sleep surveys suggest the prevalence of inadequate sleep is substantial 
and increasing.  Surveys performed several years ago demonstrated that complaints 
of inadequate sleep were commonplace, with between 20% and 30% of respondents 
complaining of inadequate sleep on a daily or several times a week basis across 
several Western nations.4-6  Recent surveys suggest this proportion is increasing with 
between 33% and 45% of Australian adults now having this complaint, depending on 
the measure employed.7  The growth of the problem over time appears to be shared 
by other nations with similar demographics.1,2,8  
 
Sleep is an active process that is essential for recuperation, memory consolidation, 
emotional modulation, performance and learning.9,10   Sleep loss impairs cognition, 
psychomotor function and mood.11 These effects have been well described in the 
medical workforce where it is associated with: lapses in attention and inability to stay 
focused; reduced motivation; compromised problem solving; confusion, irritability and 
memory lapses; impaired communication; slowed or faulty information processing and 
judgment; diminished reaction times; and indifference and loss of empathy.12  
Furthermore, short sleep has an adverse effect on physical health with small but 
measurable increases in risk of heart attacks, stroke, hypertension, obesity, diabetes, 
depression, and mortality.13-19  Experimentally, even brief periods of sleep restriction 
can impair intellectual performance, psychomotor vigilance, memory, and mood and 
increase insulin resistance and inflammatory markers.11,20  These physical and 
psychological changes adversely affect health, mood, safety and productivity both in 
the workplace and beyond it with costs in terms of health and well-being. 
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Inadequate sleep also has an economic cost relating to its effect on health, safety and 
productivity.  This has been previously demonstrated for sleep disorders.21 Estimates 
have also been made of the costs of lost productivity associated with short sleep 
duration and poor sleep patterns.22,23 A broad examination of the economic costs 
(health and safety aspects, as well as productivity implications) of inadequate sleep 
from all its sources is now warranted.  The value in estimating these costs is to 
determine whether they are sufficient to justify current or increased levels of 
expenditure on the problem.  While human costs may be well appreciated, political 
and administrative decisions are largely based on economic data.  As there is strong 
competition for available funds it is important for sleep health advocates to establish 
how the problem of inadequate sleep might rank against other health and social 
problems in terms of societal and financial cost and associated communal illness and 
injury burden.   
 
The purpose of this study was to undertake such an economic evaluation in Australia 
for the 2016-17 financial year estimating the financial cost associated with inadequate 
sleep as well as its non-financial cost, which provides a value for loss of life quality.    
 
 
METHODS  
 
A targeted literature search was conducted to establish the prevalence of inadequate 
sleep in its various forms and of the economic impacts associated with them for the 
2016-17 financial year.  Australian sources were sought to provide total costs of the 
following economic impacts: (a) the financial (monetary) costs associated with health 
care of relevant sleep disorders or of other health conditions associated with 
inadequate sleep, productivity losses, informal care provided by family or others 
outside the formal care sector, non-medical aspects of work and vehicle related 
accidents, and the deadweight loss to the economy due to inefficiencies associated 
with welfare payments and forgone taxation revenue; and (b) the non-financial (non-
monetary) costs associated with loss of life quality. 
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The proportion of the total economic costs of other health and accident outcomes 
associated with inadequate sleep were determined from the respective prevalences 
of the sleep problem and the outcome and the odds ratio linking them, using the 
population attributable fraction (PAF) methodology (see Appendix). 24 
 
Prevalences of the Various Sources of Inadequate Sleep  
The prevalences of symptoms associated with inadequate sleep, including those of 
sleep disorders and excessive daytime sleepiness, were largely obtained from a 
recent national sleep survey of the sleep health of Australian adults.7 Other data 
sources were used to supplement this sleep survey.4-6,25  Inadequate sleep was 
defined as difficulties with sleep initiation, maintenance or quality associated with the 
presence of impaired daytime alertness on several days a week or more.  The survey 
enquired about the various potential sources of inadequate sleep, including sleep 
disorders.7   Amongst the questions asked, characteristics of the following sleep 
disorders  were sought: (a) obstructive sleep apnea, which was judged to be present 
if previously diagnosed by overnight sleep study or if the respondent reported 
witnessed breathing pauses at least 3 times a week or witnessed breathing pauses a 
few times per month with loud snoring at least 3 times a week; (b) insomnia, the 
presence of which was judged using International Classification of Sleep Disorders 
(3rd edition) criteria of report of sleep initiation or maintenance problems, accompanied 
by daytime consequences (daytime sleepiness/ fatigue or exhaustion/ irritable or 
moody), at least three times a week despite adequate opportunity and circumstances 
for sleep; and (c) restless legs 3 nights a week or more.7  The prevalence estimates 
from this survey were used in the present analysis, modified where specified using 
other data from sources with similar demographics.  
  
The study examined the economic impact of inadequate sleep in all its forms.  
However, given the likely variability in their intractability and impacts on health and 
daytime performance (see below), the various sources of inadequate sleep were 
partitioned into three mutually exclusive categories to facilitate analysis: (a) excessive 
daytime sleepiness (EDS) associated with clinical sleep disorders (EDS-SD); (b) EDS 
from other sources apart from clinical sleep disorders (EDS-Other); and (c) regular 
(daily or near daily) subjective insufficient sleep where ESS is ≤10 (Insufficient Sleep).  
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The presence of excessive daytime sleepiness (EDS) was determined from the 
Epworth Sleepiness Score (ESS) using a score of >10 to define its presence.7 The 
ESS is the most commonly used measure of sleepiness in sleep research and clinical 
settings.26 It has been widely used in analysis and decision making for sleep disorder 
interventions27-29 and has been shown to be a suitable instrument for economic 
evaluation of the effects of daytime sleepiness.30  
 
The proportion of those with “EDS-SD” was estimated using the PAF methodology 
provided in the Appendix.24  The odds ratio required for this estimation (the ratio of the 
proportion of those with EDS plus a sleep disorder vs. EDS but no sleep disorder (26% 
vs. 17%, unadjusted odds ratio 1.7)) was derived from data provided by Adams from 
his study (personal communication).7 In estimating EDS-SD it was recognised that the 
risk of EDS varies between sleep disorders and that other sleep disorders besides the 
major three are associated with EDS.  While having no effect on the overall proportion 
identified as having EDS, these factors have the potential to affect the partitioning of 
those with EDS into the EDS-SD or EDS-Other categories. Nonetheless, the low 
prevalence of these additional sleep problems limits their economic impact. 
 
In people with EDS-SD, their EDS was assumed to be related to the disorder. Their 
inadequate sleep may also be associated with secondary health conditions such as 
depression and obesity. As these secondary health conditions may be related to lack 
of sleep, a proportion of their costs are included in the costs of inadequate sleep. 
 
Having calculated the proportion of those with EDS-SD, the balance of subjects with 
EDS were assigned to “EDS-Other”.   A substantial number of conditions are 
associated with EDS apart from clinical sleep disorders, including poor sleep 
behaviours, jet lag, environmental sleep disturbances and a variety of neurological, 
psychiatric and other organic diseases and various medications.31   Where a person 
has EDS-Other, the presumption is that the EDS results from the secondary condition, 
rather than vice versa. That said, there are some secondary conditions that have been 
shown to be the result of EDS – mostly injuries, but also some depression and stroke. 
These are also included in the costs of inadequate sleep. 
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The proportion of subjects with “Insufficient Sleep” was then calculated from the 
balance of those who complained of inadequate sleep but who did not have defined 
EDS.  While precise causation is not a material factor for this report, subjective 
insufficient sleep that does not result in EDS appears to be mostly attributable to 
behavioural factors.  
 
While those with sleep disorders with subjective sleepiness but not EDS were included 
in the Insufficient Sleep category; those with sleep disorders but no EDS or subjective 
sleepiness were excluded from the analysis. 
 
Estimating Proportion of Total Costs of Secondary Outcomes Attributable to 
Inadequate Sleep 
Prevalences of secondary outcomes associated with the various sources of 
inadequate sleep and the odds ratios linking them were estimated from published 
sources.  The proportion of the secondary outcome attributable to the inadequate 
sleep variant was then estimated from their respective prevalences and their linking 
odds ratios, using the PAF methodology specified in the Appendix.  Table 1 provides 
these estimates along with the sources for their derivation.  Note that while all the 
outcomes specified are linked to types of EDS-SD (obstructive sleep apnea (OSA), 
insomnia, restless legs syndrome) a more limited array are linked to EDS-Other and 
a still more limited array to Insufficient Sleep, reflecting the absence of data to 
substantiate other associations.  For example, apart from some motor vehicle 
accidents and workplace injuries (and its productivity impacts) insufficient sleep 
without EDS was assumed not to be associated with other comorbid health conditions. 
The PAFs specified in Table 1 were then used in combination with the respective total 
costs of the outcome to derive the fractional cost of the outcome that was attributable 
to inadequate sleep. 
 
Financial Costs of Inadequate Sleep and its Secondary Outcomes 
The financial costs considered were partitioned into those pertaining to health care, 
informal care, non-medical costs of workplace and motor vehicle accidents, 
productivity losses, and deadweight loss from inefficiencies associated with forgone 
taxation revenue and welfare payments. 
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Health System Costs 
The health system costs considered were both those directly associated with sleep 
disorders and those associated with conditions attributable to inadequate sleep 
including: workplace injuries and motor vehicle accidents (for all forms of inadequate 
sleep (EDS-SD, EDS-Other, Insufficient Sleep)); stroke and depression (for EDS-SD 
and EDS-Other) and heart disease and diabetes (for EDS-SD alone). The proportions 
of these related conditions and their associated costs that were attributable to an 
underlying sleep problem were calculated using the PAF methodology referred to in 
the Appendix. The estimates were limited by availability of data that adequately 
substantiates the linkages. For example, while there are adequate data to attribute a 
fraction of coronary artery disease to the OSA component of EDS-SD, insufficient data 
exist for insomnia, restless legs syndrome, EDS-Other or Insufficient Sleep. The data 
sources for established linkages are provided in Table 1. 
 
The health costs accounted for included all expenditure in the Australian health system 
for the care of sleep disorders and for the care of other inadequate sleep-associated 
health problems, including costs of hospital care, health practitioners, 
pharmaceuticals, diagnostic tests, health aids and appliances, aged care, research, 
community and public health, and capital and administration.  These data were derived 
from the latest available Australian Institute of Health and Welfare data adjusted where 
appropriate to 2016-17 values using the health price index.32-41 
 
Informal Care Costs 
Costs were estimated for time spent by carers in providing assistance and support to 
people with inadequate sleep-related health problems outside the formal healthcare 
sector. This time could be used for work activities or as leisure time.  Thus, while the 
time is given free of charge, it has associated opportunity costs due to a loss of 
economic resources. 
 
The cost calculation assumed there would be no care requirements due to inadequate 
sleep itself, only to conditions attributed to inadequate sleep that increased personal, 
household and other care needs. The distribution of these attributed conditions relative 
to the various forms of inadequate sleep is illustrated in Table 1.  Costs were based 
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on the following care requirements: (a) for motor vehicle accidents the average care 
requirement was estimated to be 4.5 hours per week; (b) for workplace injuries the 
average care requirement was estimated to be 3.7 hours per week, (c) for 
cardiovascular disease (cerebrovascular disease, coronary artery disease, congestive 
heart failure) the average care requirement was estimated to be 1.1 hours per week; 
(d) for type 2 diabetes the average care requirement was estimated to be 0.1 hours 
per week.42,43 Lack of adequate data precluded calculation of informal care costs for 
depression.   
 
The hourly cost of informal care was based on Australian Bureau of Statistics average 
weekly earnings estimates by age and gender,44 which was adjusted to the 2016-17 
financial year using growth in average weekly earnings.45 
 
Non-medical Cost of Accidents 
The PAFs for motor vehicle accidents and for workplace accidents were used to derive 
the non-medical costs of each from their respective total costs.  These costs included 
those related to legal expenses, costs of investigation, aids and modifications to the 
home, respite services, travel costs and delays, correctional services, vehicle 
unavailability and repairs, towing, insurance administration, nonvehicle property 
damage, and fire and emergency services.  The unit costs were derived from an earlier 
investigation by our group inflated to 2016-17 dollars using the consumer price index.43 
 
Productivity Losses 
Four potential productivity losses were considered: (a) reduced employment through 
early retirement or other workforce withdrawal; (b) temporary absenteeism though time 
off work; (c) presenteeism, whereby the worker is at work but is less productive; and 
(d) premature mortality. 
 
Potential double counting through estimation of the impacts of inadequate sleep itself 
and the conditions attributable to inadequate sleep (Table 1) was addressed by 
assuming that where an attributed condition existed the productivity impact was not 
compounded by inadequate sleep so that no additional productivity losses were 
assigned beyond those pertaining to the attributed conditions. 
 
11 
 
Reduced employment for EDS-SD, EDS-Other and Insufficient Sleep was estimated 
using the employment rate reductions for each of the conditions attributable to the 
sleep problem (Table 1).  These employment rate reductions were derived from a 
previous examination of the economic cost of sleep disorders in Australia undertaken 
by our group43 and were as follows: coronary artery disease 19.0%, congestive cardiac 
failure 20.7%, stroke 24.8%, depression 12.7%, and type 2 diabetes 3.1%.  The same 
source provided an estimated productivity impact of workplace injury (over multiple 
years) of 1.22 x average annual earnings of the general population.43  For motor 
vehicle accidents the productivity impact was determined by the proportion of 
accidents that result in injury sufficient to prevent a return to work, estimated to be 
0.73%.43    While it is suggested that inadequate sleep itself can undermine motivation, 
performance and employment opportunities it is not clear to what extent this occurs 
and so no separate estimation was made for this potential influence.46 
 
Absenteeism for medical conditions associated with inadequate sleep were estimated 
to be 11.5 days of sick leave per year, compared to 6 sick days per year for those 
without a chronic disease.32  For motor vehicle accidents it was estimated that 
sufferers would be away from work for an average of 9.3 days.43 For workplace injuries 
no separate estimate of costs of absenteeism was made as these were captured in 
calculation of the effects of them on reduced employment.  In addition to the cost 
impacts of the effects of attributable conditions there is an absenteeism cost of an 
estimated 2.1 days per year from EDS-SD and EDS-Other that was applied to those 
who did not have an attributable condition. This 2.1 day estimate was based on a 
simple average of estimates based on data from: (i) Lallukka et al who found a 13% 
increase in illness-related absence in the highest quartile ESS relative to the lowest 
which, applied to the average absenteeism days in Australia of 9.5 days/year equates 
to an additional 1.2 days off per year47,48 ;(ii) Adams et al who note that 17% of their 
survey participants reported taking an extra 1 to 2 days off per month because of a 
sleep related problem, with 3.5% reporting more than 3 days per month, suggesting 
additional days off could be as high as 5.2 days per person per year7 ;and (iii) Hafner 
et al who, in contrast, report no absenteeism impacts due to reduced sleep hours.49 
 
Apart from EDS, the estimated absenteeism impact of Insufficient Sleep was derived 
from the work of: (i) Lallukka et al where a weighted average of absenteeism days for 
12 
 
those who slept less than 8 hours per night suggested that an additional 0.8 days per 
year would be taken off work by those with insufficient sleep;47 and (ii) Hafner et al 
who found no discernible impact of insufficient sleep on absenteeism days.49  Given 
the latter finding the estimate based on Lallukka’s work was discounted by one half to 
0.4 additional days off work per year. 
 
Presenteeism cost estimates varied depending on whether there was EDS (either 
EDS-SD or EDS-Other) or Insufficient Sleep (without EDS) and whether or not there 
was an attributable condition associated with these.  Where there was an attributable 
condition, presenteeism impacts were conservatively assumed to have been captured 
within absenteeism or reduced employment estimates with people suffering such 
conditions either taking time off work and returning when they had recovered or exiting 
the workforce if there were persistent problems. Where there was no attributable 
condition the presenteeism impact of EDS was estimated to be 3.4% based on an 
average of the impacts estimated by Mulgrew et al of 3.7%, Hafner et al (2016) of 
2.4% for short sleep, Hafner et al (2015) of 4.4% for EDS and Rosekind et al (2010) 
of 3% for poor vs. good sleep.22,23,49,50  For Insufficient Sleep, the presenteeism impact 
was estimated to be a 1.6% reduction in productivity based on an average of estimates 
based on the work of Hafner et al (2016) of 1.4%, Hafner et al (2015) of 1.2% for 
people who sleep 6-7 hours a night vs. 7-8 hours a night and Rosekind et al for “at 
risk” vs good sleep of 2.1%.22,23,49  
 
Premature mortality estimates were derived from deaths associated with the attributed 
conditions summarized in Table 1. The mortality rates for each of these conditions 
were based on age- and gender-related estimates from a previous analysis of the 
economic cost of sleep disorders in Australia undertaken by our group.43  In the 
absence of attributed conditions, it was assumed that inadequate sleep had no 
discernible impact on mortality.   
 
Deadweight Loss 
Deadweight loss captures the cost of the substantial inefficiencies associated with 
transfer payments including disability support pension, pension supplement and rent 
assistance and reduced income and consumption taxation revenue as well as reduced 
company tax revenue due to lost earnings.  The deadweight loss calculations assume 
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there is no change to overall government spending due to reduced taxation.  The lost 
taxation revenue was estimated by applying average tax rates to the total productivity 
impacts (including informal care costs).  The inefficiency losses associated with these 
various expenses ranged from 24% for individual income to 30% for welfare payments 
to 45% for state health expenditure to 50% for reduced income for employers.43 
 
Non-Financial Costs of Inadequate Sleep and its Various Sources 
The non-financial costs of inadequate sleep derive from the less tangible costs of loss 
of life quality through pain and suffering, and premature death measured in terms of 
disability adjusted life years.  A monetary value can be assigned to this burden of 
disease estimate using the “value of a statistical life year” to calculate the value of 
years of healthy life lost due to disability or premature death.  The value of a statistical 
life year is based on willingness to pay measures for Australia.51,52 
 
The years of healthy life lost due to disability (YLDs) for EDS-SD were based on the 
disability weights for OSA, insomnia and restless legs syndrome and to their 
attributable conditions, using a simple multiplicative model to combine the impacts of 
the sleep disorder and the comorbidity where both existed.  For EDS-other or 
Insufficient Sleep the disability weight was simply that of the attributed condition.  
These disability weights were as follows:  OSA 0.105,43 insomnia 0.1,43 restless legs 
0.12,43 congestive heart failure 0.066,53 coronary artery disease 0.079,53 stroke 
0.146,53 type 2 diabetes 0.07,54 depression 0.178,53 workplace injuries 0.08, 55 and 
motor vehicle accidents 0.049.53  YLDs were then calculated by multiplying the 
prevalence of the individual and comorbid conditions by their disability weights. 
 
The years of life lost due to premature death (YLLs) were calculated as the product of 
the number of deaths related to inadequate sleep and the standard life expectancy at 
the age when death occurred.56  These estimates were based on premature death 
through health conditions attributable to inadequate sleep (Table 1), as there is 
insufficient evidence to link premature death to inadequate sleep directly. 
 
The sum of YLDs and YLLs provides the estimated disability adjusted life years lost 
from inadequate sleep.  The monetary values of these was estimated using the “value 
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of a statistical life year” of $132,210, which is the national 2014 estimate updated for 
inflation.51,52 This was applied directly to YLDs. Regarding YLLs, a compounded 
discount rate of 3% was applied to future years of life lost (determined from standard 
life expectancy at age of death) to reflect the greater value society places on a year of 
healthy life gained in the immediate future relative to subsequent years.57 
 
Sensitivity Analysis 
One-way sensitivity analyses were conducted on prevalence, the value of a statistical 
life year, the discount rate for YLLs, and estimated productivity losses. The choice of 
parameter values was either consistent with the literature that has been cited earlier, 
or within the 95% confidence interval of estimated base case values. For the lower 
case sensitivity analyses, the parameters were set so that: prevalence was 36.7%, the 
value of a statistical life year was $113,637, the discount rate for YLLs was 0%, and 
productivity losses from presenteeism for Insufficient Sleep and EDS were 1% and 2% 
respectively.  Upper case sensitivities were set so that: prevalence was 42.9%, the 
value of a statistical life year was $151,517, the discount rate for YLLs was 7%, and 
productivity losses from Insufficient Sleep and EDS were 2% and 5% respectively.  
The upper and lower bounds for the value of a statistical life year were derived from 
previously described limits. 51 
 
Currency Standardization 
All costs were expressed in United States dollars ($), using the 2016 Organisation for 
Economic Cooperation and Development purchasing power parity of 1.466 Australian 
dollars per United States dollar.58 
 
 
RESULTS 
Prevalence of the Various Sources of Inadequate Sleep and Attributable 
Conditions  
 
(a) Sleep Disorders 
Insomnia 
The estimates of insomnia prevalence vary widely depending, in part, on the 
stringency of the insomnia definition used.  The estimate of 11.3% used in this report 
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is based on a recent Australian study, using the criteria outlined in Methods.7  This 
estimate is consistent with other recent reports from countries with similar 
demographics.59-61  
 
Obstructive Sleep Apnea 
The estimated prevalence of OSA used in this report was 8.3%, based on self-report 
using the criteria outlined in Methods.7 This is consistent with current US estimates of 
clinically significant OSA of 9.5%.3 
 
Restless Legs Syndrome 
A high proportion of subjects (17.6%) reported restless legs syndrome symptoms in 
Adams et al’s recent study.7 This is close to the mid-point of the range described by a 
meta-analysis of North American and European studies.62  However the problem has 
a wide spectrum of severity.63  A prevalence estimate for clinically significant restless 
legs syndrome of 2.8% was used for this study, which is well below Adams et al’s 
estimate, but consistent with the derivations of prevalence of clinically significant 
restless legs syndrome in other reports which suggest that this lies in the 2-3% 
range.64,65   
 
 
(b) Prevalences of the Various Sources of Inadequate Sleep (EDS-SD, EDS-
Other and Insufficient Sleep) (Table 2) 
EDS was present in 19.1% of the subjects of Adams et al’s study, with 26% of those 
subjects who also had a sleep disorder having EDS, while the proportion with EDS in 
those with no coexistent sleep disorder was 17%.7  This gives an estimated unadjusted 
odds ratio of 1.7 for those who have sleep disorders to also have EDS.  Applying the 
PAF methodology (Appendix), using the prevalences of EDS (19.1%) and of sleep 
disorders (as specified above, 11.3% + 8.3% + 2.8% = 22.4%) and this odds ratio of 
1.7, provided a prevalence estimate for EDS-SD of 5.8%.  The balance of EDS (19.1% 
- 5.8%) provided a prevalence estimate for EDS-Other of 13.3%.  
 
The proportion of the community complaining of subjective insufficient sleep (with or 
without EDS) of 33% was obtained from averaging the prevalences described in 5 
recent studies of 51%7, 24%4, 28%25, 28%6, and 35%5.  Adams et al’s study found that 
16 
 
65% of those with EDS had such a complaint, yielding a balance of 20.7% (i.e. 33% - 
0.65*19.1%) of the community who have insufficient sleep without EDS.7  
 
Hence the estimated prevalence of inadequate sleep in all its forms was 39.8%, 
comprised of EDS-SD of 5.8%, EDS-Other of 13.3% and Insufficient Sleep (without 
EDS) of 20.7%.  
 
 
Financial Costs of Inadequate Sleep and its Secondary Outcomes (Tables 3 and 
4)  
Health System Costs 
The estimated health system costs of sleep disorders and conditions attributed to 
inadequate sleep for the 2016-17 financial year was $1.24 billion.  This was comprised 
of the following:  sleep disorders $158.3 million; congestive cardiac failure $9.1 million; 
coronary artery disease $77.8 million; stroke $47.5 million; type 2 diabetes $12.1 
million; depression $271.8 million; medical costs of workplace injuries $423.3 million; 
and medical costs of motor vehicle accidents $238.9 million.  Breakdowns of these 
costs by the various sources of inadequate sleep are provided in tables 3 and 4.  
   
Informal Care Costs 
The estimated total cost of informal care due to inadequate sleep in 2016-17 was 
$413.2 million.  A breakdown of these costs by the various types of inadequate sleep 
and the conditions attributable to them is provided in tables 3 and 4.   
 
Non-medical Cost of Accidents 
Applying the PAFs specified in table 1 to the total number of workplace injuries and 
motor vehicle accidents in Australia in 2016-17, it was estimated that 65,828 
workplace injuries and 66,400 motor vehicle accidents were the result of inadequate 
sleep.43  Based on our group’s previous estimates, inflated to 2016-17 dollars using 
the consumer price index, the estimated costs for each workplace injury were $1289 
for legal costs, $886 for investigations, $1328 for travel costs and $908 for aids and 
modifications, yielding a total cost of approximately $290.4 million.43  The estimated 
non-medical costs for motor vehicle accidents were $32,973 per injury yielding a total 
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cost of $2.19 billion.43  Hence the estimated total non-medical costs of accidents in 
2016-17 were $2.48 billion.  
 
Productivity Losses 
The estimated total productivity losses from inadequate sleep in Australia in 2016-17 
was $12.19 billion, comprised of $5.22 billion in reduced employment, $0.61 billion in 
premature death, $1.73 billion in absenteeism and $4.63 billion in presenteeism.  
Detailed breakdowns of these costs are provided in tables 3, 4 and 5. 
 
Deadweight Loss 
Applying the rates of efficiency loss specified in Methods, the estimated total 
deadweight loss for 2016-17 was $1.56 billion, which was comprised of efficiency 
losses from: national health expenditure of $149.9 million; state health expenditure of 
$122.0 million; welfare payments of $14.2 million; lost consumer taxes of $492.6 
million; lost company taxes of $743.2 million; and lost carer taxes of $33.8 million.  
 
Non-Financial Costs of Inadequate Sleep and its Various Sources (Tables 3, 4 
and 6) 
The estimated total disability adjusted life years lost from inadequate sleep in 2016-17 
was 228,162, consisting of 162,598 YLDs and 65,564 YLLs. A breakdown is provided 
in table 6.  Multiplying YLDs by the value of a statistical life year of $132,21152 and 
YLLs by an average discounted value of a statistical life year of $89,021 and summing 
these yielded an estimated total cost of healthy life lost through inadequate sleep of 
$27.33 billion for 2016-17.  
 
Total Cost of Inadequate Sleep 
Hence the estimated total cost of inadequate sleep in Australia in 2016-17 was $45.21 
billion, comprising $17.88 billion in financial costs and $27.33 billion in loss of 
wellbeing. 
 
Sensitivity Analysis 
The results of the sensitivity analysis are illustrated in Figure 1 and Table 7.  They 
indicate that the total cost of sleep health was most sensitive to changes in the value 
of a statistical life year and the overall prevalence rate. The total cost of inadequate 
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sleep was estimated to range from $41.38 billion to $49.21 billion in Australia in 2017 
(Table 7). 
 
DISCUSSION 
Recent surveys demonstrate that inadequate sleep is a substantial and growing 
problem in Australia and in nations with equivalent economies and demographics.1,2,5-
7 This inadequacy is due in part to untreated sleep disorders and in part to insufficient 
sleep because of work or other demands or lifestyle choice.  It comes at the expense 
of compromised cognitive and psychomotor function, mood, and physical and 
emotional well-being.11-19 These compromises adversely affect safety, productivity 
and health and have substantial associated economic costs. 
 
The purpose of the study was to quantify the economic costs associated with 
inadequate sleep in all its forms.  However, while costs relating to health, productivity, 
informal care, accident risk and deadweight losses accrue across the spectrum of 
inadequate sleep (Table 3), within this spectrum different exposures and risks apply 
for EDS-Sleep, EDS-Other and Insufficient Sleep (Table 1). For example, for 
congestive cardiac failure, coronary artery disease, and type 2 diabetes sufficient 
evidence only exists for their costs to be estimated in relation to the proportions of 
these outcomes that are related to the sleep disorders (EDS-Sleep), but not than other 
sources of inadequate sleep.  However, cerebrovascular disease and depression are 
more widely linked to include all sources of excessive daytime sleepiness (i.e. both 
EDS-Sleep and EDS-Other).  Workplace injury and motor vehicle accidents are more 
widely linked still, such that a proportion of their costs can be related to inadequate 
sleep in all its forms, although with varying odds ratios determined by the strength of 
their associations with the category of inadequate sleep under consideration (Table 
1).   
 
Our partitioning of inadequate sleep into the EDS-SD, EDS-Other and Insufficient 
Sleep categories was guided by these considerations.  EDS, as determined by an 
Epworth Sleepiness Score >10, was used in this partitioning to assign some of those 
who complain of inadequate sleep into the EDS-SD or EDS-Other categories, 
depending on whether they have evidence of a coexisting sleep disorder or not.  As 
this recognises, EDS does not capture all inadequate sleep.  However, it provided a 
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helpful means of partitioning the wider inadequate sleep group category for the 
purposes of our analysis.  The partitioning helped ensure a conservative estimate of 
costs: for example, while those with a sleep disorder and ESS >10 were included in 
the EDS-SD category, those with sleep disorders with subjective sleepiness but not 
EDS were included in the Insufficient Sleep category and those with sleep disorders 
but no EDS or subjective sleepiness were excluded from the analysis (Methods).  
Similarly, others with subjective sleepiness but no EDS were assigned to the 
Insufficient Sleep category, with its more restricted array of adequately substantiated 
linkages and lower associated odds ratios (Table 1).  
 
While there have been previous economic analyses of the cost of sleep disorders and 
of productivity losses associated with poor sleep, there has been no previous attempt 
to cost inadequate sleep from the health and safety perspectives, as well as 
productivity, as this analysis has done.  Its key finding is that the estimated total cost 
of inadequate sleep in Australia in 2016-17 was $45.21 billion, comprising $17.88 
billion in financial costs and $27.33 billion in loss of wellbeing.  This equates to 
approximately $6,117 per person affected in both financial and wellbeing costs.  
Sensitivity analysis demonstrated that these estimates were robust to variations in the 
key inputs. 
 
This is a substantial cost to the economy.  The estimated 2016-17 financial costs of 
$17.88 billion are equivalent to 1.55% of Australian gross domestic product ($1155.0 
billion) for the year.66  The estimated non-financial costs of $27.33 billion are 
equivalent to 4.6% of the total Australian burden of disease cost for the year.56  The 
Australian population in 2016-17 was 24.8 million people and so, assuming they are 
generalizable across economies with similar (Organisation for Economic Cooperation 
and Development) characteristics, the various costs would have to be adjusted for the 
population under consideration.  For the US the costs would be factored up by a 
multiple of 13 to match the 2016 US population of 323.1 million people, yielding an 
equivalent estimate of the total cost of inadequate sleep in this population of over $585 
billion for 2016-17. 
 
It is critical that such economic evaluations are done, as economic decisions demand 
them.  It is a basic political and administrative responsibility to allocate resources 
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based on costs and likely returns on investment: dollars are the lingua franca of politics 
and business.  In public health expenditure terms, sleep health languishes behind 
issues such as healthy diet, regular exercise, moderation of alcohol intake and 
smoking cessation as a priority for attention and expenditure.  In the meantime, the 
pressures on sleep health are increasing, both through ageing and weight related 
increases in sleep disorders, as well as demands from competing work, family, social, 
and social media activities.  The data in this report illustrate that, besides their impact 
on individual and societal well being, there is a substantial monetary cost to these 
issues. 
 
In setting national health priorities, Australian governments have attempted to identify 
issues that involve high communal illness and injury burden with associated high 
societal and financial cost for focused attention through public education, regulation 
and other initiatives to effect improvements in health status.  They have been 
remarkably successful in targeting issues such as diabetes, depression and smoking 
though such public health endeavours. These data suggest that sleep health now 
merits similar attention. The situation is likely to be similar in equivalent economies.22,67 
 
Large though these estimates are, they may well underestimate the economic impact 
of poor sleep health as the issues of education, learning, intellectual development and 
behavior in children and adolescents have not been considered.68,69 These problems 
have both an immediate impact and an influence on longer term economic health, 
further under-lining the importance of good sleep health to national wellbeing. 
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APPENDIX 
Methodology to Calculate Population Attributable Fractions (PAFs) 
PAFs were used to estimate the share of total costs attributable to inadequate sleep 
where there was sufficient evidence of an association between inadequate sleep and 
other health conditions.  PAFs were calculated using the following method based on 
Eide and Heuch (2001).24 First, the following two equations were solved 
simultaneously: 
 
q1.s1 + q2.s2 = p1           (1) 
(q1/(1 − q1)) / (q2/(1 − q2)) = OR        (2) 
 
where: q1 = probability of having the particular condition given that an individual has 
a sleep condition; q2 = probability of having the particular condition given that an 
individual does not have a sleep condition; s1 = share of people with a sleep condition 
= probability of having a sleep condition; s2 = share of people without a sleep condition 
= probability of not having a sleep condition; p1 = probability of having the particular 
health condition; OR = odds ratio for that particular condition for individuals with a 
sleep condition 
 
After solving these equations for q1 and q2, the following equation is derived: 
 
PAF  =  (q1 – q2).s1         (3) 
          p1 
Equation (3) was used to determine the proportion of each condition that can be said 
to be attributable to EDS-SD, EDS-Other, or Insufficient Sleep.  
 
Where epidemiological studies reported relationships in terms of a hazard ratio, the 
hazard ratios were assumed to be roughly equivalent to relative risk ratios. The PAF 
was calculated using the following equation: 
 
PAF = s1.(RR-1) / (s1.(RR-1) + 1)        (4) 
 
where: s1 = share of people with sleep condition = probability of having sleep 
condition; RR = relative risk ratio. 
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ABBREVIATIONS 
EDS: excessive daytime sleepiness; EDS-SD: excessive daytime sleepiness 
associated with clinical sleep disorders; EDS-Other: excessive daytime sleepiness 
from other sources apart from clinical sleep disorders; ESS: Epworth sleepiness score; 
IS: Insufficient Sleep; OSA: obstructive sleep apnea; PAF: population attributable 
fraction; RLS: restless legs syndrome; RR: relative risk ratio; VSLY: value of a 
statistical life year; YLD:  years of healthy life lost due to disability; YLL: years of life 
lost due to premature death. 
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FIGURE CAPTION 
 
Figure 1.  Sensitivity Analysis (Tornado diagram) of the impact on total cost of 
inadequate sleep of variations in parameter values. 
 VSLY = value of a statistical life year; YLL = years of life lost due to 
premature death. 
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Table 1.  Linkages Between Various Categories of Inadequate Sleep and Associated Conditions 
 
 EDS-SD EDS - Other Insufficient Sleep 
Condition 
Prevalence 
or Annual 
Rate (%) 
Type of 
EDS-SD 
Odds ratio PAF (%) 
Odds 
ratio 
PAF (%) 
Odds 
ratio 
PAF (%) 
Congestive Heart Failure 1.970 OSA 1.671 1.5 - - 
Coronary Artery Disease 4.970 OSA 3.272 4.8 - - 
Cerebrovascular Disease 1.673 OSA 2.974 4.8 1.475 5.0 - 
Type 2 Diabetes 8.939 OSA 1.6376 1.7 - - 
Depression 
6.277 
OSA 2.678 3.6 
1.8779 9.4 -  Insomnia 2.180 2.4 
 RLS 1.981 0.5 
Workplace Injury 
1.443 
OSA 1.582 1.3 
2.283 13.7 1.484 5.5 
 Insomnia 2.485 3.3 
Motor Vehicle Accident 1.343 OSA 2.586 3.8 1.987 10.3 1.588 11.0 
  
EDS = Excessive daytime sleepiness.  SD = sleep disorders.   PAF = population attributable fraction.  OSA = obstructive sleep 
apnea.  RLS = restless legs syndrome.  Data sources for prevalences and odds ratios are indicated on the table. 
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Table 2. Prevalences of the Various Categories of Inadequate Sleep (see text 
for references) 
 
 
Prevalence of sleep disorders (insomnia, OSA, RLS) 22.4% 
Prevalence of EDS 19.1% 
(Odds ratio of EDS in people with sleep disorders) (1.7) 
Estimated prevalence of EDS-SD 5.8% 
Estimated prevalence of EDS-Other 13.3% 
Estimated prevalence of Insufficient Sleep (without EDS) 20.7% 
Total prevalence of inadequate sleep 39.8% 
 
EDS = Excessive daytime sleepiness.  SD = sleep disorders. 
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Table 3. Breakdown of the Costs of Inadequate Sleep by Various Categories 
 
Costs of Various Categories of 
Inadequate Sleep Including Costs of 
Conditions Associated with Them 
 
TOTAL 
($ billions) 
EDS-SD 
($ billions) 
EDS-Other 
($ billions) 
Insufficient 
Sleep 
($ billions) 
 
FINANCIAL COSTS  ($ billions) 
Health  0.50 0.52 0.22  1.24 
     
Productivity     
 Reduced 
Employment 
1.27 2.69 1.26 5.22 
 Premature Death 0.24 0.26 0.11 0.61 
 Absenteeism 0.36 0.94 0.43 1.73 
 Presenteeism 0.73 2.22 1.68 4.63 
Subtotal 2.60 6.11 3.48 12.19 
     
Informal Care  0.11 0.18 0.12 0.41 
     
Other (non-medical 
accident costs) 
   
 
 Workplace Accidents 0.05 0.16 0.08 0.29 
 Vehicle Accidents 0.36 0.98 0.85 2.19 
Subtotal 0.41 1.14 0.93 2.48 
     
Deadweight Loss  0.38 0.75 0.43 1.56 
     
Total Financial Costs 4.00 8.71 5.17 17.88 
NON-FINANCIAL COSTS  ($ billions) 
Loss of Wellbeing  21.41 5.14 0.78  27.33 
TOTAL COSTS  ($ billions) 
Financial + Non-Financial  25.41 13.85 5.95  45.21 
EDS = Excessive daytime sleepiness.  SD = sleep disorders.   
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Table 4.   Breakdown of Costs ($ billions) of Inadequate Sleep and the Various Conditions Associated with  it. 
 
Costs of Various Categories of 
Inadequate Sleep not Including Costs 
of Conditions Associated with Them 
Costs of Conditions Associated with Inadequate Sleep 
 
TOTAL 
($ billions) 
EDS-SD EDS-Other 
Insufficient 
Sleep 
Heart D. Stroke Diabetes Depression 
Workplace 
Accidents 
Vehicle 
Accidents 
FINANCIAL COSTS  ($ billions) 
Health  0.16 - - 0.09 0.05 0.01 0.27 0.42 0.24  1.24 
Productivity  0.98 3.02 2.07 0.28 0.17 0.03 1.03 3.96 0.65 12.19 
Informal Care - - - 0.04 0.02 <0.01 - 0.16 0.19 0.41 
Other (non-medical 
accident costs)  
- - - - - - - 0.29 2.19 2.48 
Deadweight Loss 0.15 0.36 0.25 0.05 0.03 <0.01 0.16 0.44 0.12 1.56 
Total Financial Costs 1.29 3.38 2.32 0.46 0.27 0.04 1.46 5.27 3.39 17.88 
 
NON-FINANCIAL COSTS  ($ billions) 
Loss of Wellbeing 12.36 - - 3.56 2.32 0.72 5.80 1.12 1.45  27.33 
 
TOTAL COSTS  ($ billions) 
Financial + Non-
Financial Costs 
13.65 3.38 2.32 4.02 2.59 0.76 7.26 6.39 4.84 
 
45.21 
 
EDS = Excessive daytime sleepiness.  SD = sleep disorders.    
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Table 5. Summary of Total Productivity Costs Associated with Inadequate 
Sleep in Australia in 2016-17 ($ millions) 
 
 
Source of Productivity Loss 
EDS-SD 
($ millions) 
EDS-Other 
($ millions) 
Insufficient 
Sleep 
($ millions) 
Total 
($ millions) 
     
Reduced  Employment     
Congestive cardiac failure  13.4 - - 13.4 
Coronary artery disease 150.9 - - 150.9 
Stroke 50.3 53.2 - 103.5 
Type 2 diabetes 14.8 - - 14.8 
Depression 291.0 422.8 - 713.8 
Workplace injuries 695.4 2,064.4 1,132.0 3,891.8 
Motor vehicle accidents 55.3 150.4 129.2 334.9 
Subtotal 1,271.1 2,690.8 1,261.2 5,223.1 
     
Premature Death     
Congestive cardiac failure  2.5 - - 2.5 
Coronary artery disease 88.3 - - 88.3 
Stroke 25.0 26.5 - 51.5 
Type 2 diabetes 4.8 - - 4.8 
Depression 63.6 92.3 - 155.9 
Workplace injuries 13.3 39.5 21.7 74.5 
Motor vehicle accidents 38.4 104.3 89.6 232.3 
Subtotal 235.9 262.6 111.3 609.7 
     
Absenteeism     
Congestive cardiac failure  2.1 - - 2.1 
Coronary artery disease 19.3 - - 19.3 
Stroke 5.6 5.9 - 11.5 
Type 2 diabetes 5.5 - - 5.5 
Depression 65.7 95.5 - 161.2 
Workplace injuries - - - - 
Motor vehicle accidents 13.9 37.7 32.4 84.0 
No attributed conditions 252.5 796.5 396.7 1,445.7 
Subtotal 364.6 935.6 429.1 1,729.3 
     
Presenteeism     
No attributed conditions 731.5 2,223.6 1,677.1 4,632.2 
Subtotal 731.5 2,223.6 1,677.1 4,632.2 
     
     
TOTAL 2,603.1 6,112.6 3,478.7 12,194.4 
EDS = Excessive daytime sleepiness.  SD = sleep disorders. 
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Table 6.   Estimated Disability adjusted life years (DALYs) lost from inadequate 
sleep in Australia, 2016-17 
 
Condition 
EDS-SD 
 
(DALYs) 
EDS-Other 
 
(DALYs) 
Insufficient 
Sleep 
(DALYs) 
Total 
 
(DALYs) 
Congestive heart failure 1,858 - - 1,858 
Coronary artery disease 30,833 - - 30,833 
Stroke 11,070 10,390 - 21,460 
Type 2 diabetes 5,688 - - 5,688 
Depression 23,371 24,595 - 47,966 
Workplace injuries 2,702 4,790 2,626 10,118 
Motor vehicle accidents 3,679 7,021 6,029 16,729 
Inadequate sleep with no 
attributed condition 
93,510 - - 93,510 
     
TOTAL 172,712 46,795 8,655 228,162 
 
EDS = Excessive daytime sleepiness.  SD = sleep disorders.    
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Table 7. One-way sensitivity analyses 
 
Variable Financial 
Loss of 
Well-being 
Total 
Base case 17.88 27.33 45.21 
    
Prevalence (base case = 39.8%)    
Lower (36.7%) 16.57 25.28 41.85 
Upper (42.9%) 19.22 29.43 48.64 
    
VSLY (base case = $132,210)    
Lower ($113,637) 17.88 23.49 41.38 
Upper ($151,517) 17.88 31.33 49.21 
    
Discount rate for YLLs (base case = 3%)    
Lower (0%) 17.88 30.17 48.05 
Upper (7%) 17.88 25.48 43.36 
    
Presenteeism (IS = 1.6%, EDS = 3.4%)    
Lower (IS = 1%, EDS = 2%) 15.86 27.33 43.19 
Upper (IS = 2%, EDS = 5%) 20.01 27.33 47.34 
VSLY = value of a statistical life year; YLL = years of life lost due to premature death; 
IS = Insufficient Sleep; EDS = excessive daytime sleepiness. 
 
 
 
